Clinical trial
A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
NCT02966353 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2017
- Completion date
- February 15, 2019
- Enrollment
- 51 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
post-essential thrombocythemia myelofibrosis, post-polycythemia vera-myelofibrosis, primary myelofibrosis